Report Company Directory

ONWARD HOLDINGS CO LTD

Onward Holdings Co. Ltd.

• Quantitative Monographs "日本における体系的株主還元" Stephens by UBS AG
• Quantitative Monographs "Systematic shareholder returns in Japan" Stephens by UBS AG
• 小売セクターの投資戦略 (2021年2月) by Mizuho Securities
• ONWARD HOLDINGS sees a downgrade to Slightly Negative on account of less fundamental stars by TheScreener
• Retail brand equity importance to grow post-COVID-19 by Mizuho Securities
• Announces sale of stake in Jil Sander; progress on structural reforms a positive by Mizuho Securities
• 中小型株ウィークリー (2021年3月9日号) by Mizuho Securities
• ジルサンダー事業の株式譲渡を発表、構造改革が更に進んだ点を評価 by Mizuho Securities
• カバレッジ削除 by Mizuho Securities
• Post-Covid19で重要度を増す小売業のブランド・エクイティ by Mizuho Securities

ONWARD MEDICAL NV

• Life Sciences Conference 25 Sep 2025 by KBC Securities
• Onward Medical Publishes ARCIM data on blood pressure regulation in Nature Medicine by KBC Securities
• Morning Notes : NEXTA BB, SOF BB, UCB BB, BTLS BB, ONWD BB, EXO NA by KBC Securities
• Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy by GlobeNewsWire
• Onward Medical Receives CE Mark certification for ARC-EX in the EU by KBC Securities
• Morning Notes : PNL NA, VPK NA, ONWD BB by KBC Securities
• ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe by GlobeNewsWire
• Onward Medical 1H25 update shows ARC-EX launch on track, home use label by YE25 by KBC Securities
• Morning Notes : ACKB BB, AGS BB, GIMB BB, ONWD BB by KBC Securities
• ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025 by GlobeNewsWire

ONWARD OPPORTUNITIES LIMITED

• European Morning Research Summary by Stifel
• 1H review: ARC-EX sales granularity, EmpowerBP analysis and opex breakdown by Stifel
• European Morning Research Summary by Stifel
• H1 review: 30 Units Placed, Pipeline Advancing – Onward Positioned for H2 Upside by Stifel
• European Morning Research Summary by Stifel
• FDA IDE approval: ARC-IM moves into the big leagues by Stifel
• European Morning Research Summary by Stifel
• ARC-EX is almost home, 510(k) submitted and 2025 expectations on track by Stifel
• Strong first quarter, commercial momentum building by Stifel
• European Morning Research Summary by Stifel

Onward Technologies

• Onward Technologies Ltd: 1 director by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research